Pre-made Eblasakimab benchmark antibody ( Whole mAb, anti-IL13RA1 therapeutic antibody, Anti-CD213A1/CT19/IL-13Ra/NR4 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-661

Pre-Made Eblasakimab biosimilar, Whole mAb, Anti-IL13RA1 Antibody: Anti-CD213A1/CT19/IL-13Ra/NR4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-661-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Eblasakimab biosimilar, Whole mAb, Anti-IL13RA1 Antibody: Anti-CD213A1/CT19/IL-13Ra/NR4 therapeutic antibody
INN Name Eblasakimab
TargetIL13RA1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4hwe:HL/4hwb:HL
Year Proposed2021
Year Recommendedna
CompaniesASLAN Pharmaceuticals
Conditions Approvedna
Conditions ActiveAtopic dermatitis
Conditions Discontinuedna
Development Techna